State Street SPDR S&P Biotech ETF XBI
148.40 USD -10.70 (-6.73%)
At closeNov 5, 2026, 7:39 PM EST
147.29 -1.11 -0.75%
After hours · Nov 5, 7:39 PM ET
148.25 Day range 157.61
106.30 52-week range 169.89
- YTD
- +21.71%
- 1 year
- +35.88%
- Market cap
- 8.32B
- YTD return
- +21.71%
- 1-year return
- +35.88%
- Volume
- 13.73M
- Avg volume
- 8.97M
- Open
- 157.45
- Previous close
- 159.10
- Day's range
- 148.25 – 157.61
- 52-week range
- 106.30 – 169.89
1m -8.27 (-5.28%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 156.14
- 200-day average
- 141.93
Next earnings
Consensus EPS estimate 0.00.
About State Street SPDR S&P Biotech ETF
In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI").
News
Do You Own Tempus AI Without Knowing It? Check These ETFs After Its Earnings Surge 
Regeneron Surges 13.55%: Here's What It Means for Your Health Care ETFs 
ETFs That You May Consider Amid a Strengthening Biotech Outlook 
Should You Invest in the State Street SPDR S&P Biotech ETF (XBI)? 
Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy? 
Why $55 Million Flowed Into a Triple-Leveraged Biotech ETF Worth Less Than $600 Million 
SPDR S&P Biotech ETF $XBI Stock Sold by Banque Pictet & Cie SA 
Traders Purchase Large Volume of Call Options on SPDR S&P Biotech ETF (NYSEARCA:XBI) 
From Laggard to Leader: The Surprising Comeback of Healthcare 
Biotech's Rebound Reality: Surging M&A Deals Meet Deep Retail Skepticism
Your note
Sign in to keep a note on XBI — it syncs with the Stock Master app.